Loading
companiesCompany
Oakwood Laboratories
Oakwood Laboratories is an Ohio specialist in long-acting injectable microspheres whose leuprolide depot formulations for prostate cancer went through the phase 3 trials it led.
Also called: Oakwood Laboratories, LLCOakwood Labs
Overview
Oakwood Laboratories, founded in 1997 in Oakwood Village, Ohio, develops sustained-release injectable microsphere formulations. Its leuprolide acetate depot products for advanced prostate cancer, developed to match the established monthly and three-monthly injections, were taken through phase 3 trials registered on ClinicalTrials.gov under Oakwood as lead sponsor, and the company also contract-manufactures depots for partners.
Headquarters
Oakwood Village, OH, US
Scorecard
All companies#221of 1244 companies, score 24
- approved products +6
- targets +2
- modalities +2
- regions +6
- registry trials +8
1 approved, 0 in phase 3, 0 earlier, 1 targets, 16 registry studies. Formula on the scorecards page.
Type
Stage
Large private
Website
Founded
1997
ApprovedGnRH agonist depot
Leuprolide (leuprorelin) and GnRH agonists · Lupron / Eligard / Camcevi
Leuprolide is the injectable that shuts off testosterone production, the foundation of hormone therapy for prostate cancer since the 1980s; it is also used for ovarian suppression in premenopausal breast cancer.
Similar pages
- CompanyForesee Pharmaceuticals
Shares Leuprolide (leuprorelin) and GnRH agonists, Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyPregLem
- CompanyIonis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Prostate cancer.
- CompanyAgennix
- CompanyLisata Therapeutics
- CompanyImmunitor
- CompanyEmergent BioSolutions
- CompanyHarbour BioMed
cancers
drugs
ApprovedGnRH agonist depot
Leuprolide (leuprorelin) and GnRH agonists · Lupron / Eligard / Camcevi